Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications.

ABSTRACT:

Background

The rising incidence rate of prostate cancer (PCa) has promoted the development of new diagnostic and therapeutic radiopharmaceuticals during the last decades. Promising improvements have been achieved in clinical practice using prostate specific membrane antigen (PSMA) labeled agents, including specific antibodies and small molecular weight inhibitors. Focusing on molecular docking studies, this review aims to highlight the progress in the design of PSMA targeted agents for a potential use in nuclear medicine.

Results

Although the first development of radiopharmaceuticals able to specifically recognize PSMA was exclusively oriented to macromolecule protein structure such as radiolabeled monoclonal antibodies and derivatives, the isolation of the crystal structure

SUBMITTER: Pastorino S 

PROVIDER: S-EPMC7509769 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature